The Challenge
After progression on a KRAS inhibitor trial, Sarai faced conflicting biomarker results, was uncertain about trial eligibility, and lacked a lead oncologist to coordinate her care.
Our Impact
Cancer Commons clarified her MSI and HLA status, recommended a liquid biopsy to uncover resistance mutations, curated viable trial options, and connected her with supportive resources and potential lead oncologists.
The Outcome
Sarai gained clarity, a concrete plan for next steps, and renewed confidence in navigating her care—expressing deep gratitude for finally feeling guided and supported.
